$1.91
+0.07 (+3.69%)
Open$1.90
Previous Close$1.84
Day High$1.95
Day Low$1.76
52W High$10.42
52W Low$1.10
Volume—
Avg Volume16.3K
Market Cap2.11M
P/E Ratio—
EPS$-5.33
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+940.8% upside
Current
$1.91
$1.91
Target
$19.88
$19.88
$13.54
$19.88 avg
$24.91
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 204.9K | 202.9K | 653.1K |
| Net Income | -12,015,114 | -10,707,597 | 116.0K |
| Profit Margin | -5,863.7% | -5,570.5% | 17.8% |
| EBITDA | -12,279,081 | -11,550,774 | 172.6K |
| Free Cash Flow | — | — | 101.3K |
| Rev Growth | +1.0% | +1.0% | -9.1% |
| Debt/Equity | — | — | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |